Cost-effectiveness of a Novel Hypoglycaemia Programme: The 'HARPdoc vs BGAT' RCT.

Andrew Healey Tayana Soukup Nick Sevdalis Ioannis Bakolis Samantha Cross Simon R Heller Augustin BrooksDulmini KariyawasamElena Toschi Linda A Gonder-Frederick Marietta Stadler Helen RogersKimberley GoldsmithPratik Choudhary Nicole de Zoysa Stephanie A Amielnull null

Published in: Diabetic medicine : a journal of the British Diabetic Association (2024)

Addressing health cognitions in people with treatment-resistant hypoglycaemia achieved cost-effectiveness compared to an alternative approach through improved QoL and reduced need for medical services, including hospital admissions. Compared to BGAT, HARPdoc offers a cost-effective adjunct to educational and technological solutions for problematic hypoglycaemia.

Keyphrases

type diabetes
healthcare
mental health
public health
primary care
health information
randomized controlled trial
clinical trial
risk assessment
health insurance